LYEL Lyell Immunopharma, Inc.

XNAS 13.45 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

LYEL $13.45 —
Key stats
$13.45
52-Week Range
$7.20 – $45.00
YTD
-53.59%
IV Rank (30D)
49.32
Straddle Price
$4.95
P/C Vol Ratio
3.47
Market Cap
$0.4B
Open
$13.74
Day Range
$13.38 – $13.98
Volume
116,188
Prev Close
$13.89
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY1.26
Cost of Equity (CAPM)11.20% (VRP-adj)
WACC11.70%
Volatility Risk Premium-0.7pp (IV − HV30), ERP adj -18bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-132.4%
Book / Price56.8% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-933100.0%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$11.01 (Market Anchor value)
SMA 20 / Bollinger Mid$12.98
Bollinger Width / SMA2078.4% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
83%
20-Day Fair Value
≈ by Dec 18, 2026
$13.73
α +0.5% rank 53%
conviction
53%
40-Day Fair Value
≈ by Jan 18, 2027
$13.91
α +1.8% rank 60%
conviction
87%
60-Day Fair Value
≈ by Feb 16, 2027
$14.01
α +2.6% rank 55%
conviction
83%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 40.2× · 3 peers
Peer EV/EBITDA n/a 0% median 19.7× · 3 peers
Peer P/B $28.00 25% median 3.5× · 3 peers
Peer P/S $0.00 25% median 3.8× · 3 peers
Market Anchor (SMA50) $11.01 0% stability 0% (BB-width)
Options Expected (B-L 30d) $12.87 49% 15 strikes · skew +0.77
As of 2026-11-19 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.4B
Employees
161
List Date
2021-06-17
CIK
0001806952
Last Earnings
Nov 4 before open · +43.3% vs ±45.5% expected
Headquarters
South San Francisco, CA
Homepage
https://www.lyell.com

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-tar…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan---26.23%-2.68%-13.27%-8.48%-17.18%-13.57%
Feb--21.07%-34.45%57.84%21.61%-3.11%12.59%
Mar---26.49%-1.67%-27.36%-18.66%-16.76%-18.19%
Apr---4.29%-21.62%-0.46%-1.88%-5.19%-6.69%
May---23.90%49.07%18.88%-7.09%-16.80%4.03%
Jun-3.85%56.73%-4.50%-45.08%7.54%-18.08%-1.21%
Jul-9.43%-7.01%-6.77%1.90%25.31%2.13%1.02%
Aug7.27%20.94%-14.34%-3.33%0.54%11.27%3.73%
Sep-8.07%2.37%-37.18%-1.43%42.33%-32.60%-5.76%
Oct4.89%-21.07%15.73%-24.98%0.66%17.32%-1.24%
Nov-32.46%-28.28%3.59%-15.62%45.02%25.55%*-0.37%
Dec-17.22%-13.90%1.57%-36.00%39.28%---5.25%
Total-49.64%-57.94%-57.24%-74.58%223.57%-51.30%-11.19%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $13.18
SMA 50: $11.04
SMA 200: $16.16
Current: $13.48
EMA 12: $14.00
EMA 26: $12.92
MACD: 1.0735 | Signal: -0.1239
BULLISH
ADX (14): 38.09
TREND
+DI: 24.54
−DI: 16.92

Momentum Oscillators

RSI (14): 53.65
NEUTRAL
Stoch %K: 44.26
Stoch %D: 50.27
Williams %R: -58.58

Volume & Volatility

BB Upper: $18.00
BB Lower: $8.37
NEUTRAL
OBV: -2,793,200
Vol SMA 20: 241,950
Vol ROC: -82.57%
ATR: $1.29
True Range: $0.60
HV 20: 148.8%
HV 30: 132.1%
HV 60: 100.6%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis
Written before LYEL’s Nov 4 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

Overall assessment: BEARISH (confidence level: 6/10)

Key drivers:

  • Bearish technical signals, including MACD histogram below signal line
  • High volatility (beta >1.5) with strong short-term momentum indicators
  • Recent news sentiment remains positive, but may not be enough to overcome bearish technical signals

Primary risks:

  • Technical breakdown risk if price breaks below $15.89 support level
  • High short-term volatility leading to potential trading range congestion

Investment thesis: The stock is expected to trend downwards due to the strong bearish technical signals and high volatility, despite positive news sentiment.

Recent news sentiment impact: Positive news headlines are being offset by the bearish technical signals and high volatility, resulting in a neutral-to-bearish market narrative.

Technical Analysis

Trend direction:

  • Short-term: Bearish (1-4 weeks)
  • Medium-term: Neutral to bearish (1-3 months)
  • Long-term: Bullish (3-12 months)

Support/resistance levels:

  • Critical price level: $15.89 (lower Bollinger Band)
  • Key resistance level: $19.30 (SMA 20)

Momentum signals:

  • RSI interpretation: Neutral (36.12) with no clear buy/sell signal
  • MACD signal: Bearish (MACD histogram below signal line)
  • Bollinger Bands position: Squeeze, indicating potential volatility increase

Volume analysis:

  • Volume trends: Decreasing volume over the past few days
  • Institutional interest signals: Unusual put activity suggests increased bearish sentiment among institutions

News & Sentiment Analysis

Recent headlines summary:

  • Positive news headlines suggest continued momentum for the company's clinical trials and treatments.
  • Neutral headline from Century Therapeutics' board appointments does not have a significant impact on market narrative.

Sentiment assessment: Aggregate news sentiment remains positive (4/5), but may not be enough to overcome bearish technical signals.

Catalyst identification:

  • Upcoming events: ASH Annual Meeting and Exposition, potential catalysts for the company's clinical trials
  • Regulatory changes: FDA approval of treatments or indication could significantly impact market narrative

Market narrative: The news headlines remain positive, but the bearish technical signals and high volatility suggest a neutral-to-bearish market narrative.

Risk & Volatility Assessment

Risk interpretation:

  • Beta >1.5 suggests high risk relative to the market
  • Volatility regime: High volatility with increasing short-term uncertainty

Options market signals:

  • IV rank: 26.8% (Medium) indicates historically medium volatility
  • Current IV: 121.0% suggests high implied volatility
  • Expected move: $4.90, indicating potential trading range congestion

Downside protection:

  • Support levels: Critical price level at $15.89 (lower Bollinger Band)
  • Risk management considerations: Stop-loss levels around $16.50 and position sizing considerations for investors

Market Context & Positioning

Sector performance:

  • Relative strength vs sector/market: Neutral to bearish

Institutional activity:

  • Volume patterns suggesting institutional interest: Decreasing volume over the past few days, indicating potential lack of support among institutions.

Correlation analysis:

  • R-squared interpretation: 0.22 suggests low correlation with market (high beta), increasing risk for investors

Relative valuation:

  • Position within trading range: The stock is currently in a neutral-to-bearish zone, suggesting limited upside and increased downside risk.

Key Levels & Action Items

Critical price levels:

  • Support level: $15.89 (lower Bollinger Band)
  • Resistance level: $19.30 (SMA 20)

Breakout/breakdown levels:

  • Technical breakdown risk if price breaks below $15.89 support level
  • Breakout potential above $22.72 upper Bollinger Band

Time-sensitive catalysts:

  • Earnings dates, FDA approvals, product launches from the company and its peers

Risk management:

  • Stop-loss levels around $16.50
  • Position sizing considerations for investors based on risk tolerance and market conditions
Generated
Earnings History
15 of 15 under expected move
Avg Expected Move
65.28%
Avg Actual Move
7.55%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2023-05-04 Pre-Market 16.32% 4.31% 0.26x Within
2023-08-08 Pre-Market 11.11% 1.91% 0.17x Within
2023-11-07 Pre-Market 16.67% 2.27% 0.14x Within
2024-02-28 Pre-Market 23.61% 0.35% 0.01x Within
2024-05-06 Pre-Market 14.16% 7.63% 0.54x Within
2024-08-07 After-Close 441.49% 6.38% 0.01x Within
2024-11-07 Pre-Market 104.73% 17.57% 0.17x Within
2025-03-11 Pre-Market 157.28% 2.29% 0.01x Within
2025-05-13 Pre-Market 29.54% 4.03% 0.14x Within
2025-08-12 Pre-Market 9.22% 0.09% 0.01x Within
2025-11-12 Pre-Market 28.70% 2.20% 0.08x Within
2026-03-12 After-Close 19.98% 14.23% 0.71x Within
2026-05-06 Pre-Market 23.76% 1.12% 0.05x Within
2026-08-06 Pre-Market 37.17% 5.65% 0.15x Within
2026-11-04 Pre-Market 45.50% 43.27% 0.95x Within

Earnings calendar: this week’s reports with expected vs actual moves →

LYEL Options Activity & IV Rank

LYEL IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 162.8%
7-DTE IV: —
Expected Move: $4.95
7-DTE Move: $4.90
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 393
Put Volume: 1,365
P/C Volume: 3.473
BEARISH
Call OI: 748
Put OI: 1,615
P/C OI: 2.159
Total OI: 2,363

ATM Options Pricing

ATM Call: $2.45
ATM Put: $2.50
Call %: 18.2%
Put %: 18.6%

Chain Summary

Chain Volume: 1,758
Chain OI: 2,363
Last Updated: 11/19/2026

LYEL Implied Volatility

30-day IV
162.8%
Nov 19
IV rank
49Medium
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much LYEL actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 45th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
45%
vs own history
GEX tilt
-0.48
OI-weighted, today
Vanna tilt
-0.28
δ-sensitivity to IV
Charm tilt
-0.77
δ-decay vs time
Charm tilt -0.77: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 7 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 185.6% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)49.3MediumNov 19

Embed LYEL IV rank

LYEL's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$4.95Nov 19
Beta Analysis

Risk Metrics

Beta: 1.7800
Alpha: -2.59%
Correlation: 0.2644
R-Squared: 7.0%
Stock Volatility: 92.6%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own LYEL
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$5.2M
0.00%
#2038 of 3716-19.9%13F
Renaissance Technologies Hedge fund
Jim Simons
$1.9M
0.00%
#1993 of 3151+45.3%13F
Point72 Hedge fund
Steve Cohen
$366K
0.00%
#1698 of 1945+22.5%13F
Citadel Hedge fund
Ken Griffin
$263K
0.00%
#5201 of 6285-95.1%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

LYEL Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 22,558,000 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

101 filers12,879,853 shares$152.56M value57.10% of float
# Filer Shares Value % of Total % of Float Period
1 ARCH Venture Management, LLC 3,247,162 $45.53M 29.84% 14.39% 2026-06-30
2 GSK plc 1,512,659 $14.81M 9.71% 6.71% 2026-09-30
3 Almitas Capital LLC 581,407 $8.17M 5.35% 2.58% 2026-06-30
4 BlackRock, Inc. Custodian 799,057 $7.82M 5.13% 3.54% 2026-09-30
5 Orland Properties Ltd 754,698 $7.39M 4.84% 3.35% 2026-09-30
6 Vanguard Capital Management LLC 748,848 $7.33M 4.81% 3.32% 2026-09-30
7 Decheng Capital LLC 692,050 $6.78M 4.44% 3.07% 2026-09-30
8 Foresite Capital Management V, LLC 476,386 $6.69M 4.39% 2.11% 2026-06-30
9 Millennium Management LLC Custodian 367,473 $5.16M 3.38% 1.63% 2026-06-30
10 Opaleye Management Inc. 344,025 $4.83M 3.17% 1.53% 2026-06-30
11 venBio Partners LLC 337,697 $4.74M 3.11% 1.50% 2026-06-30
12 Alphabet Inc. 293,256 $2.87M 1.88% 1.30% 2026-09-30
13 Geode Capital Management, LLC Custodian 274,598 $2.69M 1.76% 1.22% 2026-09-30
14 HSG Holding Ltd 152,299 $2.14M 1.40% 0.68% 2026-06-30
15 State Street Corp 191,807 $1.88M 1.23% 0.85% 2026-09-30
16 RENAISSANCE TECHNOLOGIES LLC 189,122 $1.85M 1.21% 0.84% 2026-09-30
17 Northern Trust Corp Custodian 118,500 $1.66M 1.09% 0.53% 2026-06-30
18 Charles Schwab Investment Management, Inc. 107,570 $1.51M 0.99% 0.48% 2026-06-30
19 Velan Capital Investment Management LP 105,000 $1.48M 0.97% 0.47% 2026-06-30
20 Qube Research & Technologies Ltd 142,401 $1.39M 0.91% 0.63% 2026-09-30
21 Goldman Sachs Group Inc Custodian 86,779 $1.22M 0.80% 0.38% 2026-06-30
22 ACADIAN ASSET MANAGEMENT LLC 97,951 $953.00K 0.62% 0.43% 2026-09-30
23 Morgan Stanley Custodian 89,423 $875.45K 0.57% 0.40% 2026-09-30
24 MIC Capital Management UK LLP 87,028 $852.00K 0.56% 0.39% 2026-09-30
25 Vanguard Portfolio Management LLC 86,227 $844.16K 0.55% 0.38% 2026-09-30
4 filers$753.51K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $363.89K 48.29% 2026-06-30
2 Citadel Advisors LLC Custodian $238.85K 31.70% 2026-06-30
3 Jane Street Group, LLC Custodian $146.85K 19.49% 2026-09-30
4 Simplex Trading, LLC Custodian $3.92K 0.52% 2026-09-30
4 filers$2.62M notional
# Filer Notional Value % of Total Period
1 Jane Street Group, LLC Custodian $2.15M 82.27% 2026-09-30
2 Citadel Advisors LLC Custodian $251.50K 9.62% 2026-06-30
3 Susquehanna International Group, LLP Custodian $199.51K 7.63% 2026-06-30
4 Simplex Trading, LLC Custodian $12.73K 0.49% 2026-09-30

LYEL Insider Trading (Form 4)

Latest: 2026-11-12
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-12 Gary K. Lee Chief Scientific Officer Sell (S) −129 $15.93 -$2.1K EDGAR
2026-11-12 Lynn Seely President and CEO Sell (S) −545 $15.93 -$8.7K EDGAR
2026-11-12 Veronica Sanchez Bulis VP, Corporate Controller Sell (S) −416 $15.93 -$6.6K EDGAR
2026-11-12 Stephen J. Hill Chief Operating Officer Sell (S) −88 $15.93 -$1.4K EDGAR
2026-11-05 ARCH Venture Fund IX, L.P. 10%+ Owner Buy (P) +2,321,262 $10.77 $25.00M EDGAR
2026-11-05 ARCH Venture Partners XIII, L.P. 10%+ Owner Buy (P) +2,321,262 $10.77 $25.00M EDGAR
2026-10-13 Jarrad Mattieu Aguirre Chief Medical Officer Sell (S) −422 $8.63 -$3.6K EDGAR
2026-09-10 David Shook Chief Medical Officer Sell (S) −500 $12.70 -$6.3K EDGAR
2026-09-10 Jarrad Mattieu Aguirre Chief Medical Officer Award (A) — — EDGAR
2026-08-25 Gary K. Lee Chief Scientific Officer Sell (S) −1,457 $15.54 -$22.6K EDGAR
2026-08-25 Stephen J. Hill Chief Operating Officer Sell (S) −989 $15.54 -$15.4K EDGAR
2026-08-25 Lynn Seely President and CEO Sell (S) −9,589 $15.54 -$149.0K EDGAR
2026-08-11 Veronica Sanchez Bulis VP, Corporate Controller Sell (S) −621 $14.34 -$8.9K EDGAR
2026-08-11 Lynn Seely President and CEO Sell (S) −390 $14.34 -$5.6K EDGAR
2026-08-11 Gary K. Lee Chief Scientific Officer Sell (S) −131 $14.34 -$1.9K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

LYEL Insider Holdings

18 insiders · @ $13.62
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 ARCH Venture Partners XIII, L.P. 10%+ Owner 3,747,790 $51.06M $25.00M 1 2026-11-05
2 ARCH Venture Fund IX, L.P. 10%+ Owner 3,747,790 $51.06M $25.00M 1 2026-11-05
3 Innovative Cellular Therapeutics Holdings Ltd 10%+ Owner 2,774,980 $37.81M -$274 6 2026-07-27
4 Keith Crandell 10%+ Owner 1,820,634 $24.81M $0 1 2025-07-29
5 ARCH Venture Partners IX, LLC 10%+ Owner 1,426,528 $19.44M $12.50M 1 2026-03-09
6 Paul L Berns 10%+ Owner 1,426,528 $19.44M $12.50M 1 2026-03-09
7 Richard Klausner Director 190,557 $2.60M -$108.4K 10 2026-06-12
8 Lynn Seely President and CEO 63,354 $863.2K -$340.4K 16 2026-11-12
9 Charles W. Newton Chief Financial Officer 25,306 $344.8K $93.5K 8 2025-08-22
10 David Shook Chief Medical Officer 20,423 $278.3K -$31.3K 4 2026-09-10
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

LYEL Board & Officers

As of SEC filings through Nov 12, 2026

Directors 8

Officers 8

10% owners 15

Changes in the last 10 years (51)
Aug 31, 2026Jarrad Mattieu Aguirre became Chief Medical Officer
May 18, 2026Innovative Cellular Therapeutics Holdings Ltd became a 10% owner
Mar 9, 2026Smital Shah became Chief Fin. and Bus. Officer
Oct 31, 2025Veronica Sanchez Bulis became VP, Corporate Controller
Sep 15, 2025The company announced the departure of Charles W. Newton as Chief Financial Officer in an SEC filing
Jul 29, 2025Robert Nelsen no longer listed as a director in SEC filings
Jul 25, 2025Steven Gillis became a 10% owner
Jul 25, 2025Paul L Berns became a 10% owner
Jul 25, 2025Kristina Burow became a 10% owner
Jul 25, 2025ARCH Venture Partners XIII, LLC became a 10% owner
Jul 25, 2025ARCH Venture Partners XIII, L.P. became a 10% owner
Jul 25, 2025ARCH Venture Fund XIII, L.P. became a 10% owner
Jun 9, 2025Mark Bachleda became a director
Jun 9, 2025Mark A Meltz became General Counsel
Jun 9, 2025David Shook became Chief Medical Officer
Mar 27, 2025The company announced the departure of Matthew Lang as Chief Business Officer in an SEC filing
Nov 22, 2024The company announced the departure of Hans Edgar Bishop from the board in an SEC filing
Oct 31, 2024Sumant Ramachandra became a director
Feb 13, 2024Stephen J. Hill listed as Chief Operating Officer (previously Chief Technical Ops. Officer) in SEC filings
Jul 1, 2023Matthew Lang became Chief Business Officer
Not reported recently (3)
  • Tina M. Albertson · Last reported as Chief Medical Officer in an SEC filing dated Feb 28, 2023
  • Heather D Turner · Last reported as Chief General Counsel in an SEC filing dated Mar 18, 2022
  • Glaxosmithkline Plc · Last reported as a 10% owner in an SEC filing dated Jun 23, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

LYEL Proposed Insider Sales (Form 144)

Latest: 2023-08-15
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2023-08-15 Klausner Richard Director 4,485 $10.3K 2023-08-15 Raymond James & Associates, Inc. — EDGAR
2023-08-15 Klausner Richard Director 4,485 $10.3K 2023-08-15 Raymond James & Associates, Inc. — EDGAR
2023-08-15 Klausner Richard Director 44,565 $102.1K 2023-08-15 Raymond James & Associates, Inc. — EDGAR
2023-08-15 Klausner Richard Director 4,485 $10.3K 2023-08-15 Raymond James & Associates, Inc. — EDGAR
2023-07-17 Klausner Richard Officer, Director 14,500 $42.0K 2023-07-13 Raymond James & Associates, Inc. — EDGAR
2023-07-17 Klausner Richard Officer, Director 3,300 $9.6K 2023-07-13 Raymond James & Associates, Inc. — EDGAR
2023-07-17 Klausner Richard Officer, Director 3,300 $9.6K 2023-07-13 Raymond James & Associates, Inc. — EDGAR
2023-07-17 Klausner Richard Officer, Director 3,300 $9.6K 2023-07-13 Raymond James & Associates, Inc. — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-04 Earnings results EDGAR
2026-11-04 Unregistered share sale EDGAR
2026-09-10 Other events EDGAR
2026-08-06 Earnings results EDGAR
2026-06-15 Shareholder vote results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-04 0001628280-26-070171 EDGAR
2026-08-06 0001628280-26-054367 EDGAR
ETF Holders
26 ETFs hold LYEL
25 shown · $14.95M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $5.3M — 2026-10-31
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.00% $3.1M $75.0B 2026-11-17
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $1.4M — 2026-10-31
4 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.01% $1.2M $13.6B 2026-11-17
5 SCHA Schwab U.S. Small-Cap ETF Nport 0.00% $957,049 — 2026-08-31
6 IBB iShares Biotechnology ETF iShares (BlackRock) 0.01% $823,303 $10.9B 2026-11-17
7 VTWO Vanguard Russell 2000 ETF Vanguard 0.00% $554,385 — 2026-10-31
8 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.03% $352,221 $1.2B 2026-11-17
9 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.01% $327,943 $3.1B 2026-11-17
10 VHT Vanguard Health Care ETF Vanguard 0.00% $316,219 — 2026-10-31
11 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $130,326 — 2026-08-31
12 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.00% $116,835 — 2026-07-31
13 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $106,489 — 2026-11-17
14 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.01% $88,000 — 2026-10-31
15 RSSL Global X Russell 2000 ETF Global X 0.01% $61,977 — 2026-11-18
16 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $26,807 — 2026-11-17
17 IBBQ Invesco Nasdaq Biotechnology ETF Invesco 0.02% $26,780 — 2026-11-17
18 DXUV Dimensional US Vector Equity ETF Dimensional 0.00% $25,918 — 2026-11-17
19 BIB ProShares Ultra NASDAQ Biotechnology ProShares 0.01% $14,279 — 2026-11-18
20 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $12,707 — 2026-10-31
21 ITWO ProShares Russell 2000 High Income ETF ProShares 0.00% $6,626 — 2026-11-18
22 AVUS Avantis U.S. Equity ETF Avantis 0.00% $4,730 $14.4B 2026-11-17
23 URTY ProShares UltraPro Russell2000 ProShares 0.00% $4,639 — 2026-11-18
24 UWM ProShares Ultra Russell2000 ProShares 0.00% $3,056 — 2026-11-18
25 HDG ProShares Hedge Replication ETF ProShares 0.00% $153 — 2026-11-18
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-11.73
TTM Revenue
$15.00K
TTM Net Income
$-255.16M
TTM Op. Cash Flow
$-139.25M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '262026-09-30$3.00K$-45.53M$-1.86$-34.57M
Q2 '262026-06-30$4.00K$-44.76M$-1.92$-33.92M
Q1 '262026-03-31$2.00K$-24.15M$-1.10$-38.51M
Q4 '252025-12-31$6.00K$-140.72M$-6.85$-32.25M
Q3 '252025-09-30$15.00K$-38.85M$-2.13$-28.58M
Q2 '252025-06-30$8.00K$-42.68M$-2.89$-34.46M
Q1 '252025-03-31$7.00K$-52.20M$-3.54$-54.74M
Q4 '242024-12-31$11.00K$-191.94M$-14.40$-47.24M
Q3 '242024-09-30$34.00K$-44.58M$-3.48$-35.04M
Q2 '242024-06-30$13.00K$-45.81M$-3.59$-38.09M
Q1 '242024-03-31$3.00K$-60.67M$-4.80$-42.02M
Q4 '232023-12-31$13.00K$-52.93M$-4.00$-40.63M
Q3 2026 • period ending 2026-09-30 • filed 2026-11-04
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.60
P/S
20542.82
EV/EBITDA
—
EV/Sales
14405.95
ROE
-132.4%
ROA
-93.2%
Div Yield
0.00%
FCF Yield
-45.19%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$308.14M
as of 2026-11-19

LYEL vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
AMGN Amgen Inc $247.7B 25.6 +8.2% +34.8% 40
GILD Gilead Sciences Inc $211.2B — +6.5% +38.0% 54
VRTX Vertex Pharmaceuticals Inc $135.4B 34.4 +10.5% +18.2% 59
REGN Regeneron Pharmaceuticals Inc $99.1B 20.6 +18.6% +20.2% 55
MRNA Moderna, Inc. Common Stock $83.7B — +13.1% +535.8% 34
BIIB Biogen Inc. Common Stock $37.1B 106.7 +2.3% +40.4% 100
RVMD Revolution Medicines, Inc. Common Stock $35.2B — — +109.6% 75
ROIV Roivant Sciences Ltd. Common Shares $28.0B — +102.1% +80.8% 61
LYEL Lyell Immunopharma, Inc. Common Stock $438M — −63.4% −53.0% 50
Peer median $91.4B 30.0 +10.5% +39.2% 57

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
1.41M
SI % of Float
15.95%
Days to Cover
10.43
Short Vol Ratio
56.0%
Free Float
8.84M
Float %
36.1%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-08-17